PegBio Co Ltd
http://www.pegbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PegBio Co Ltd
China Biotech IPO Drought Lingers But HK Sees First Of 2024
Biotech IPOs on the Chinese mainland have dried up since June 2023 due to regulatory tightening, but Hong Kong is still open to listings of pre-revenue ventures and has seen its first offering of this year.
China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.
Biotechs Stage No-Show As China’s STAR Market Marks Third Anniversary
To date this year, not a single innovative drug-focused biotech has filed for an initial public offering on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Apart from a suspected tightening of listing rules, IPO disclosures and the plummeting share prices of public companies seem to be looming large over bioventures aiming considering floating on the bourse.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Paige Biotechnology
- Paige Biomedicine (Suzhou) Co., Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice